{"filings":[{"id":2244276,"accession_number":"0001753926-26-001479","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2026-08-13T20:13:36+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare Q2 revenue down 68.5% to $2.3M; net loss $8.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.3M vs $7.3M in Q2 2025; 11 units sold vs 19, with 8 units deferred to Q3 on financing timing.","Net loss $8.7M ($0.53/share) vs $1.0M ($0.06/share); includes $5.7M valuation allowance on deferred tax assets.","Adjusted EBITDA negative $3.0M vs negative $1.8M; gross margin 34.8% vs 39.7% on product mix.","CMS proposed 26% increase in hospital-based SRT delivery code, if finalized would improve provider economics.","Management cites strong pipeline, expanded Asia-Pacific activity (Australia, New Zealand); expects strong H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":888317,"accession_number":"0001753926-26-000983","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2026-06-05T20:08:48+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sensus Healthcare enters into $15M revolving credit facility with City National Bank of Florida","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$15M revolving credit facility; initial $2M available secured by $2.23M cash collateral and blanket asset lien.","Interest rate at SOFR + 3% per annum; matures June 5, 2027 subject to mutual extension.","Remaining $13M restricted until four consecutive quarters of positive net income and DSCR ≥1.50.","Prior credit facility with Fifth Third Bank (successor to Comerica) terminated.","Covenants restrict asset sales, additional debt, liens, and removal of CEO/President/CFO without lender consent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":788117,"accession_number":"0001753926-26-000960","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2026-06-02T12:26:11+00:00","items":["5.07"],"status":"ready","headline":"Sensus Healthcare shareholders re-elect directors, approve advisory vote on pay, ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eric Sachetta and Michael J. Sardano re-elected as Class II directors for three-year terms.","Non-binding advisory vote on executive compensation approved with 4.7M for vs 856K against.","Ratification of Carr, Riggs & Ingram as auditor for FY 2026 approved with 10.7M for.","Annual Meeting held on May 29, 2026; all proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93176,"accession_number":"0001753926-26-000782","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare Q1 revenue drops to $3.4M; cash $18.3M, no debt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $3.4M, down 59% vs $8.3M in Q1 2025; no sales to historically largest customer (15 units in prior year).","Shipped 14 SRT systems (10 direct, 4 placements) vs 30 in prior year; excluding largest customer sales, revenue up from $2.7M.","Gross margin fell to 29.2% from 52.2% due to product mix and Fair Deal placements; adjusted EBITDA -$4.2M vs -$2.5M.","New CPT codes for SRT effective Jan 1, 2026 drove higher inquiry levels and pipeline activity.","Launched Sensus Healthcare Financial Services and Sensus Link; Fair Deal treatment volumes up 8% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":3394000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104586,"accession_number":"0001753926-26-000315","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare Q4 2025 revenue $4.9M, net loss $3.2M; CMS code boost effective Jan 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $4.9M, down from $13.1M YoY; net loss $3.2M ($0.19/sh) vs net income $1.5M ($0.09/sh) in Q4 2024.","Shipped 14 SRT systems in Q4 (8 US, 6 international), up from 6 in Q3 excluding largest customer.","Ended 2025 with $22.1M cash and no debt; full-year revenue $27.5M, net loss $7.7M.","CMS published dedicated CPT codes for SRT effective Jan 1, 2026, providing 300% per-fraction increase and reimbursement certainty.","Expects sequential revenue growth in Q1 2026 and full-year profitability; FDA program delivered 11,411 treatments (+8x YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":27482000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104585,"accession_number":"0001753926-26-000147","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Sensus Healthcare dismisses BPB, appoints CRI as auditor after asset acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee simultaneously dismissed BPB and approved CRI as independent auditor on Jan 13, 2026.","CRI acquired certain assets of BPB's capital markets practice effective Jan 1, 2026.","BPB's 2024 audit report contained no adverse opinion or qualification; no disagreements with BPB occurred.","Material weakness in IT general controls reported in Q2 2024; remediated by Dec 31, 2024, with no misstatements.","BPB furnished a letter to the SEC dated Jan 16, 2026, filed as Exhibit 16.1, agreeing with the Company's disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104584,"accession_number":"0001753926-26-000088","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sensus Healthcare appoints Larry Biscotti to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Larry Biscotti appointed as Class I director effective January 5, 2026, term expiring at 2028 annual meeting.","Biscotti brings 25+ years of med device/healthcare tech experience; currently President, Imaging for US/Canada at GE HealthCare.","Board now has six directors, including four independent; Biscotti determined independent per Nasdaq rules.","Compensation as non-employee director on pro-rata basis; committee assignments not yet determined."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120859,"accession_number":"0001753926-25-001772","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sensus Healthcare appoints Eric Sachetta to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Sachetta, 37, fills vacancy from death of Director William McCall.","Sachetta is Chief Wealth Services Officer of Sachetta, LLC, a financial advisory firm.","Appointed as Class II director for term expiring at 2026 annual meeting.","Board determined Sachetta is independent; he joined the Audit Committee.","Sachetta holds CFP, ChFC designations and a BS from Bentley University."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120858,"accession_number":"0001753926-25-001710","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Q3 2025: Revenue down 21.6% to $6.9M; net loss of $0.9M vs profit of $1.2M a year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $0.9M ($0.06 per share) vs net income of $1.2M ($0.07 diluted) in Q3 2024.","Revenue fell 21.6% to $6.9M; gross margin dropped to 39.1% from 59.1%.","Shipped 16 SRT systems (vs 27 last year), including 3 to China; 21 FDA sites active.","CMS published first-ever dedicated CPT® codes for SRT, improving reimbursement certainty.","Exited quarter with $24.5M cash, no debt; nearly 100 systems in inventory."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":22543000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137462,"accession_number":"0001753926-25-001254","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare Q2 2025 revenue $7.3M, net loss $1.0M; ships 19 SRT systems, FDA volume up 27% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.3M vs $9.2M YoY; net loss $1.0M ($0.06/sh) vs net income $1.6M ($0.10/sh) in Q2 2024.","Shipped 19 SRT systems, including 4 to China; signed 5 new Fair Deal Agreements, 4 live; FDA volume +27% seq.","Gross margin fell to 39.7% from 58.7% on lower sales and higher service costs; adjusted EBITDA negative $1.8M.","Ended quarter with $22.2M cash and no debt; engaged Radiology Oncology Systems as distribution partner for hospitals.","Proposed Physician Fee Schedule expected to align outpatient SRT reimbursement with hospital rates starting Jan 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":15659000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154790,"accession_number":"0001753926-25-000919","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sensus Healthcare shareholders elect director, approve incentive plan amendment at May 27 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Anthony Petrelli re-elected as Class I director for three-year term; votes: 4,325,657 for, 1,563,543 against, 13,305 abstentions.","Amendment to 2017 Incentive Plan approved (5,186,278 for, 495,719 against, 220,508 abstentions) to extend term and increase shares.","Non-binding advisory vote on executive compensation passes (5,057,473 for, 346,796 against, 498,236 abstentions).","Ratification of Berkowitz Pollack Brant as auditor for FY2025 approved (11,113,695 for, 66,087 against, 205,805 abstentions)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154789,"accession_number":"0001753926-25-000851","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare Q1 revenues $8.3M, net loss $2.6M vs. net income $2.3M year ago; forecasts profitability rest of year","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $8.3M, down 22% YoY from $10.7M; net loss $0.16 per share vs. net income $0.14 per diluted share.","Gross margin 53.0% vs. 62.6% year ago due to lower sales and higher service costs.","Shipped 21 SRT systems, including 15 to a large customer; treatment volume from FDAs increased 65% sequentially.","Management expects profitability in each of next three quarters and full year; affirms 3-5 additional multisite FDA customers this year.","R&D expense $2.6M vs. $0.9M driven by lobbying costs for billing code reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":8344000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173305,"accession_number":"0001753926-25-000213","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sensus Healthcare resumes $3M share repurchase program, citing compelling opportunity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Resumes purchases under $3.0M buyback program approved August 2023; 9,427 shares already repurchased.","CEO Joe Sardano says repurchase is compelling at current prices; completed similar $3M program in 2022.","Program is discretionary; may be suspended or discontinued at any time at company's discretion.","Company remains confident in growth prospects and strategic initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173304,"accession_number":"0001753926-25-000183","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare Q4 revenue $13.1M, EPS $0.09; record 39 SRT shipments; Q1 sales expected lower","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $13.1M (+4% YoY); full-year revenue $41.8M (+71% YoY).","Q4 2024 net income $1.5M ($0.09 diluted EPS), down from $4.2M ($0.26) in Q4 2023.","Shipped record 39 SRT systems in Q4 and 115 systems in full year (up 18% and 74% YoY).","Ended year with $22.1M cash and cash equivalents, no debt.","Guidance: Q1 2025 sales could be considerably lower than Q1 2024; full-year sales growth expected."],"consensus_eps_estimate":null,"consensus_eps_actual":0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":41807000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190317,"accession_number":"0001213900-24-099516","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Q3 revenues double to $8.8M; net income $1.2M vs loss; targets >50 IG-SRT deals by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $8.8M (+127% YoY); net income $1.2M ($0.07 diluted EPS) vs net loss $1.5M ($0.09 loss) in Q3 2023.","Adjusted EBITDA $1.6M vs negative $1.7M; shipped 27 systems (11 in Q3 2023).","Signed 22 IG-SRT units under Fair Deal as of Sep 30; expects >50 by year-end, generating recurring revenue in 2025.","Cash $22.6M, no debt; gross margin improved to 59.3% from 51.0%.","Sold SRT system to Providence Swedish Hospital; strong interest at ASTRO conference."],"consensus_eps_estimate":null,"consensus_eps_actual":0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":28741000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190316,"accession_number":"0001213900-24-098068","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare Q3 2024 revenue doubles to $8.8M; net income of $0.07 per diluted share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $8.8M (+127% YoY); net income $1.2M vs net loss $1.5M in Q3 2023.","Shipped 27 systems (11 in Q3 2023); cash $22.6M, no debt.","Adjusted EBITDA $1.6M (negative $1.7M a year ago).","Signed Fair Deal Agreement with Platinum Dermatology (130+ clinics); 22 agreements since March 2024.","Sold SRT system to Providence Swedish Hospital; expects recurring revenue from Fair Deal Agreements in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":28741000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206815,"accession_number":"0001213900-24-077707","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Marcum resigns as Sensus auditor over merger conflict; BPB appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum resigned Sept 5, 2024, effective immediately, due to independence concerns from its merger with CBIZ Inc., which provides HR/insurance services to Sensus.","No disagreements with Marcum on accounting principles; prior audit reports for 2022 and 2023 were unqualified.","Marcum noted a material weakness in IT general controls as of June 30, 2024, but no misstatements resulted.","Audit Committee appointed Berkowitz Pollack Brant (BPB) as new independent auditor on Sept 11, 2024.","Company did not consult BPB on any accounting matters prior to appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206814,"accession_number":"0001213900-24-066621","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare Q2 2024 revenue $9.2M (+104% YoY); net income $1.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $9.2M vs $4.5M in Q2 2023, up 104%; 23 systems shipped (including 3 to Asia) vs 13 last year.","Net income $1.6M ($0.10 diluted EPS) vs net loss of $0.4M ($0.02 loss per share) in Q2 2023.","Adjusted EBITDA $2.1M vs negative $1.0M in prior-year quarter.","Signed 15 Fair Deal Agreements for SRT-100 Vision units since March 2024; recurring revenue expected in 2025.","Cash and equivalents $19.0M, no debt; accounts receivable $18.3M vs $10.6M at Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":19902000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224081,"accession_number":"0001213900-24-050044","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sensus Healthcare holds 2024 annual meeting; reelects two directors, approves charter amendment and say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Megan Cornish and Joseph Sardano elected as Class III directors for three-year term ending 2027.","Stockholders approved amendment to certificate of incorporation to permit officer exculpation under Delaware law.","Non-binding advisory vote approved 2023 executive compensation; 8,552,812 for, 416,554 against.","Ratified Marcum LLP as independent auditor for fiscal year 2024; 13,111,490 for, 52,543 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224080,"accession_number":"0001213900-24-048133","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sensus Healthcare director Dr. John Heinrich resigns from board effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. John Heinrich resigned from Sensus Healthcare's Board of Directors on May 30, 2024, effective immediately.","Resignation was not due to any disagreement with the company requiring disclosure under Item 5.02(a).","No replacement has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224079,"accession_number":"0001213900-24-041314","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare Q1 revenue $10.7M (up 214% YoY); net income $2.3M vs loss of $1.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $10.7M, up 214% from $3.4M; shipped 26 systems vs 10 YoY.","Net income $2.3M ($0.14 diluted EPS) vs net loss $1.9M ($0.12 loss) YoY.","Adjusted EBITDA $3.0M vs negative $2.7M YoY.","Launched 'Fair Deal Agreement' recurring revenue program; cash $14.7M, no debt.","Sold first SRT-100 Vision in Asia (Taiwan) and first veterinary unit outside U.S. (Israel)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":10663000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243437,"accession_number":"0001213900-24-011598","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare Q4 revenue $12.6M, net income $4.2M; introduces recurring revenue model","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $12.6M (vs $13.1M YoY) but up 3x sequentially from Q3 $3.9M; net income $4.2M ($0.26 diluted EPS) vs $2.8M YoY.","Full-year 2023 net income positive at $0.03 diluted EPS; shipped 66 SRT units (33 in Q4). Cash $23.1M, no debt.","Introduced recurring revenue model for SRT-100 Vision; first placement completed with multiple in pipeline.","Appointed President & General Counsel Michael Sardano to Board of Directors.","Engaged CureRays for clinical oversight and studies to expand SRT indications beyond skin cancer and keloids."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":24405000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243436,"accession_number":"0001213900-24-009622","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Samuel O'Rear to retire at 2024 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Samuel O'Rear will not stand for reelection at the 2024 annual meeting.","O'Rear's retirement is not due to any disagreement with the company.","No replacement for the director position has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243435,"accession_number":"0001213900-24-004491","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2024-01-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sensus Healthcare appoints Michael Sardano to Board of Directors effective Feb 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Sardano, currently President, General Counsel, and Corporate Secretary, appointed as Class II director.","Term expires at the 2026 annual meeting; no committee assignments.","Mr. Sardano is the son of Chairman and CEO Joseph C. Sardano.","No arrangement or understanding with any other person led to the appointment.","He has been employed by the Company since 2013 in various legal and management roles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260821,"accession_number":"0001213900-23-085220","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare Q3 revenues down 57% YoY to $3.9M; net loss of $1.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenues $3.9M vs $9.0M Q3 2022; net loss $1.5M ($0.09/sh) vs net income $1.8M ($0.11) prior year.","Adjusted EBITDA negative $1.7M vs positive $2.3M a year ago.","Shipped 11 SRT units (3 outside US, 5 to one large customer); cash $20.5M, no debt.","Board approved $3.0M stock repurchase program.","Submitted 510(k) for aesthetic drug delivery system; expects completion by end of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":11838000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278105,"accession_number":"0001213900-23-076674","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2023-09-14T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Sensus Healthcare enters $10M revolving credit facility with Comerica, terminates SVB facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $10M revolving credit facility with Comerica Bank, interest at SOFR + 2.5%, due on demand.","Facility secured by all assets of Sensus Healthcare.","Financial covenant requires maintaining $3.5M unencumbered liquid assets in a Comerica account.","Prior $15M revolving facility with Silicon Valley Bridge Bank voluntarily terminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278104,"accession_number":"0001213900-23-065938","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sensus Healthcare authorizes $3M share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $3M in common stock repurchases; timing and amounts at management's discretion.","CEO Joe Sardano says buyback reflects optimism about future and is a top cash use.","Purchases may be made via open-market, block trades, or other methods; program can be suspended anytime.","Company is not obligated to repurchase any specific amount of stock under the program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278103,"accession_number":"0001213900-23-062982","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare Q2 revenue $4.5M (-63% YoY), net loss $0.4M vs $3.5M profit last year","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.5M, down 63% YoY from $12.1M; net loss $0.4M ($0.02/sh) vs net income $3.5M ($0.21/sh) in Q2 2022.","Shipped 13 SRT systems (down from 33 YoY) but up from 10 in Q1; total installed base 708 systems worldwide.","Cash $20.1M, no debt; gross margin 57.9% vs 68.3% a year ago on lower volume and higher vendor costs.","Guidance: expects to ship at least 60 SRT systems in 2023 and return to profitability in H2 2023.","New UK/Ireland distribution with MIS Healthcare; first sale in Ireland; international expansion progressing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":7941000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296192,"accession_number":"0001213900-23-046768","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Sensus Healthcare enters CFO employment agreement; annual meeting votes on director elections and charter amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO Javier Rampolla employment agreement: base salary $250,000, target annual bonus $100,000, severance provisions.","Annual meeting elects William McCall and Megan Cornish as Class II directors for three-year terms.","Stockholders approved amendment to 2017 Incentive Plan to increase shares issuable.","Amendment to limit officer liability failed to achieve majority of outstanding shares and was not approved.","Advisory vote on executive compensation approved; Marcum LLP ratified as auditor for FY2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296191,"accession_number":"0001213900-23-035978","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare Q1 2023 revenue $3.4M; net loss $1.9M; expects H2 profitability","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.4M vs $10.3M YoY; shipped 10 SRT systems vs 33.","Net loss $1.9M ($0.12 per share) vs net income $16.1M ($0.97 per share) in Q1 2022 (included $12.8M gain).","Gross margin fell to 47.1% from 68.9% due to lower volume and vendor cost increases.","Ended Q1 with $19.3M cash, no debt; expects >60 SRT shipments in 2023 and return to profitability in H2.","Management cites inflation impacting dermatologists' cash flow; higher selling & marketing expense."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":3414000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316695,"accession_number":"0001213900-23-009738","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2023-02-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare Q4 net income $2.8M ($0.17 EPS); FY22 revenue up 65% to $44.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $13.1M flat YoY; net income $2.8M ($0.17 diluted EPS) vs $5.3M ($0.32).","Full-year revenue $44.5M (+65% YoY); cash $25.5M, no debt; adjusted EBITDA $4.3M vs $5.6M.","Gross margin fell to 63.7% from 68.0% on higher manufacturing costs and inflation.","Expects continued topline growth in Q1 2023 and full-year profitability; multiple 510(k) submissions planned in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":44532000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316694,"accession_number":"0001213900-23-001717","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Preliminary FY2022 revenue exceeds $44M (60% growth); profitable Q4 and FY; COO appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2022 revenues expected to exceed $13M; full-year 2022 revenues exceed $44M (60% growth over 2021).","Sensus expects both Q4 and full-year 2022 to be profitable; Q4 aesthetics revenue over $500K.","Magdalena Martinez named COO, replacing Nicolas Soro, effective January 3, 2023. She previously served as VP of Operations.","Company plans to expand sales force, increase trade show presence, and submit new technologies to FDA in H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":44532000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334952,"accession_number":"0001213900-22-068983","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare Q3 revenue $9.0M (+64% YoY), EPS $0.11 vs $0.01; introduces Silk laser system","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $9.0M (+64% YoY); net income $1.8M ($0.11 diluted EPS) vs $0.2M ($0.01) a year ago.","Adjusted EBITDA $2.3M vs $0.5M; cash $37.6M, no debt.","Introduced Silk™ laser hair removal system; launched SRT-100 Vision upgrades with new ultrasound.","Shipped first of 10 TDI Systems to Hair Enhancement Centers; shipped 4 SRT units to China.","Expects Q4 growth and full-year profitability; notes Hurricane Ian impact on Florida customers."],"consensus_eps_estimate":null,"consensus_eps_actual":1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":31428000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352394,"accession_number":"0001213900-22-044758","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare Q2 revenue up 124% to $12.1M; diluted EPS $0.21 vs $(0.02) YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $12.1M, up 124% from $5.4M in Q2 2021; net income $3.5M vs net loss $(0.3M).","Diluted EPS $0.21 vs $(0.02); adjusted EBITDA $4.7M vs $(0.1M).","Gross margin improved to 68.6% from 61.1%; cash and equivalents $33.7M.","Received orders for 10 TransDermal Infusion Systems from Hair Enhancement Centers.","Affirms expectations for continued Q3 growth and full-year profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":1.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":22417000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369934,"accession_number":"0001213900-22-031850","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2022-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sensus Healthcare stockholders elect directors, approve advisory proposals at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["John Heinrich and Anthony Petrelli elected as Class I directors for 3-year terms.","Non-binding advisory vote on 2021 executive compensation approved (8,036,995 for).","Annual advisory vote on executive compensation frequency affirmed by stockholders.","Marcum LLP ratified as independent auditor for FY2022 (11,064,295 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369933,"accession_number":"0001213900-22-024232","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare Q1 revenue $10.3M (+237% YoY); net income $0.97/share; launches new product, share buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $10.3M, up 237% YoY; net income $16.1M ($0.97 diluted) vs net loss $1.1M.","Adjusted EBITDA $16.9M vs $(0.8M); gross margin expanded to 69.1% from 51.6%.","Sold non-core asset for $15.0M cash, recorded $12.8M gain; launched TransDermal Infusion product.","Board approved $3.0M share repurchase program; cash balance $32.8M.","Affirms Q2 and FY 2022 profitability expectations."],"consensus_eps_estimate":null,"consensus_eps_actual":0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":10338000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389055,"accession_number":"0001213900-22-011247","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2022-03-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sensus Healthcare announces $3M share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $3M in common stock repurchases via open market or block trades.","Program has no expiration date and may be modified, suspended, or discontinued at any time.","Chairman and CEO Joe Sardano cited confidence in the company's future and sustained profitability.","Repurchases will be based on market conditions, stock price, and management discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389054,"accession_number":"0001213900-22-010531","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2022-03-03T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"Sensus Healthcare sells Sculptura product assets to Empyrean Medical Systems for $15M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price of $15,000,000 in cash plus assumption of certain liabilities relating to Sculptura assets.","Buyer's CEO Kalman Fishman is a former Sensus executive; sale was arm's-length and not deemed a material relationship.","Sale closed on February 25, 2022, the same date as the agreement.","Assets include intellectual property (patents, trademarks, software), tangible personal property, and assigned contracts.","Sensus retains all other operations; proceeds from sale are for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389053,"accession_number":"0001213900-22-006461","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2022-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare Q4 record revenue $13.0M, EPS $0.32; FY 2021 revenue $27.0M up 182%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $13.0M (+156% YoY); net income $5.3M ($0.32 diluted EPS) vs $1.0M ($0.06) in Q4 2020.","Full-year 2021 revenue $27.0M (+182%); diluted EPS $0.25 vs loss of $0.42 in 2020.","Shipped record 35 systems in Q4, including 3 to China; received Ministry of Health license renewal through 2026.","Signed exclusive U.S. distribution agreement for TransDermal Infusion System for needle-less drug delivery.","Affirms expectation for Q1 2022 continued growth and full-year 2022 profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":27042000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389052,"accession_number":"0001213900-22-004504","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2022-01-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sensus Healthcare elects Michael Sardano as President; Joseph Sardano remains Chairman and CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Sardano elected President effective Jan 27, 2022; he also continues as General Counsel.","Joseph C. Sardano resigned as President but remains Chairman and CEO.","Stephen Cohen resigned as EVP Strategic Initiatives and Dermatology effective Jan 28, 2022.","No details on compensation or reasons for changes provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389051,"accession_number":"0001213900-22-000684","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2022-01-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare expects record Q4 2021 sales over $25M, profitable Q4 and FY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Expects record Q4 sales; full-year 2021 revenue over $25M.","Expects positive EBITDA and net income for Q4 and full year.","Q4 sales include three SRT systems shipped to China.","Also expects profitability for Q1 2022.","TransDermal Infusion System featured at Winter Clinical Dermatology Conference on Jan 15."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":27042000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406986,"accession_number":"0001213900-21-056757","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare Q3 revenue $5.5M (+244% YoY); reports first profitable Q3, net income $0.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.5M, up 244% from $1.6M in Q3 2020; net income $0.2M vs loss of $1.7M.","Adjusted EBITDA positive $0.5M vs negative $1.5M; shipped 14 systems including 8 SRT-100 Vision.","Affirms Q4 and full-year 2021 profitability; five-year license renewal from Chinese Health Authority through Dec 2026.","Diluted EPS $0.01 vs ($0.10); gross margin expanded to 57.9% from 41.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":14017000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425992,"accession_number":"0001213900-21-040518","cik":1494891,"company_name":"Sensus Healthcare, Inc.","ticker":"SRTS","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensus Healthcare Q2 revenue up 358% YoY to $5.4M; net loss narrows to $0.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.4M, up 358% YoY and 77% sequentially; shipped 17 systems including 7 SRT-100 Vision.","Net loss improved to $(0.3)M ($0.02 loss per share) from $(2.6)M loss in Q2 2020; Adjusted EBITDA $(0.1)M vs $(2.3)M.","Cash $15.2M at June 30, 2021; worldwide installed base of SRT systems reached 515.","CMS increased reimbursement for SRT effective Jan 2021; new leasing options; expanding international in China and India.","Management cautiously optimistic for sequential growth; on track to profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":8492000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":51690867.597444095,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}